Adapt to survive and thrive: the time is now for adaptive platform trials for preterm birth
- PMID: 39855752
- DOI: 10.1016/S2352-4642(24)00328-6
Adapt to survive and thrive: the time is now for adaptive platform trials for preterm birth
Abstract
In this Viewpoint, we discuss the challenges facing perinatal clinical researchers, many of which are unique to this field, and how traditional two-arm randomised trials using frequentist analysis might no longer be fit for purpose for perinatology. We propose a solution: the adoption of adaptive platform trials (APTs) with Bayesian methodology to address perinatal research questions to improve outcomes of preterm birth. APTs use a master protocol as a foundation to efficiently assess multiple interventions simultaneously for a particular disease. APTs can study these interventions in a perpetual manner, with interventions allowed to enter or leave the platform on the basis of preplanned decision algorithms. In this Viewpoint, we outline the ways in which APTs can overcome some of the issues facing perinatal clinical research, and the challenges and essential requirements for the design and implementation of perinatal APTs that should be considered.
Trial registration: ClinicalTrials.gov NCT06461429.
Crown Copyright © 2025 Published by Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests All authors are investigators on the planned PLATIPUS perinatal adaptive platform trial (NCT06461429). PLATIPUS is supported by funding from Australia's National Health and Medical Research Council (GNT2032384) and Medical Research Future Fund (GNT2031127). BJM (GNT2016662) and KJL (GNT2017498) are supported by National Health and Medical Research Council fellowships. CLW is supported by a Clinical Research Fellowship from the Norman Beischer Medical Research Foundation (Australia). All other authors declare no competing interests.
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Adaptive platform trials: definition, design, conduct and reporting considerations.Nat Rev Drug Discov. 2019 Oct;18(10):797-807. doi: 10.1038/s41573-019-0034-3. Epub 2019 Aug 28. Nat Rev Drug Discov. 2019. PMID: 31462747 Review.
-
DHA supplementation for early preterm birth prevention: An application of Bayesian finite mixture models to adaptive clinical trial design optimization.Contemp Clin Trials. 2024 Sep;144:107633. doi: 10.1016/j.cct.2024.107633. Epub 2024 Jul 14. Contemp Clin Trials. 2024. PMID: 39013543
-
Omega-3 fatty acid addition during pregnancy.Cochrane Database Syst Rev. 2018 Nov 15;11(11):CD003402. doi: 10.1002/14651858.CD003402.pub3. Cochrane Database Syst Rev. 2018. PMID: 30480773 Free PMC article.
-
Quality Improvement in Perinatal Medicine and Translation of Preterm Birth Research Findings into Clinical Care.Clin Perinatol. 2018 Jun;45(2):155-163. doi: 10.1016/j.clp.2018.01.003. Epub 2018 Feb 23. Clin Perinatol. 2018. PMID: 29747880 Free PMC article. Review.
Cited by
-
What is the Role of Caffeine in the Management of Preterm Infants?Curr Treat Options Pediatr. 2025;11(1):16. doi: 10.1007/s40746-025-00329-5. Epub 2025 Jul 2. Curr Treat Options Pediatr. 2025. PMID: 40620533 Free PMC article. Review.
References
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical